Beijing Tianfukang Medical Technology Co., Ltd. stands out as a pioneering medical device company dedicated to the exploration and development of brain-computer interface (BCI) and neuromodulation technologies. Leveraging its cutting-edge technology platform, "Brain-Computer Interface + Precise Closed-Loop Modulation of Nerve Bundles," the company has cultivated a suite of core technologies. Recently, it successfully closed an angel round of financing, raising tens of millions of yuan. This round was spearheaded by Sequoia Capital China, with notable participation from the Yuanming Brain Science Fund. WinX Capital played a pivotal role in facilitating the financing process and will continue to serve as the exclusive financial advisor for future rounds. Tianfukang Medical has honed in on the technology of "precise closed-loop modulation of nerve bundles," establishing a comprehensive, in-house development capability. This encompasses flexible electrodes, specialized brain-computer chips, adaptive closed-loop algorithms, and more, collectively forming an innovative product matrix that is globally recognized. The company has taken a pioneering step by developing a brain-computer interface system aimed at reconstructing hand motor function following a stroke. This system has undergone preliminary validation of its complete technical pathway through non-human primate studies. Moreover, Tianfukang Medical has forged a strategic partnership with Beijing Tiantan Hospital to accelerate the clinical translation of its technologies and products. Investors are bullish on the company's technological prowess, the strength of its team, and its immense development potential.